In particular, PPARα downregulates bile acid synthesis by inhibiting CYP enzymes, e.g., CYP7A1 and CYP27A1 [50], making it a desirable target for the pharmacological treatment of cholestatic liver diseases. Here, PPARA is linked to Cholestatic liver disease.